| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
IPN-60090 manufacturers
- IPN60090
-
- $107.00
-
2026-07-14
- CAS:1853164-83-6
- Purity: 99.76%
- Supply Ability: 10g
- IPN60090
-
- $107.00
-
2026-07-14
- CAS:1853164-83-6
- Purity: 99.76%
- Supply Ability: 10g
|
| | IPN-60090 Basic information |
| Product Name: | IPN-60090 | | Synonyms: | IPN-60090;GLS1-IN-1;IACS-6274(IPN60090);IPN-60090 ( IACS-6274);IPN60090,IPN-60090;1-[(2R)-4-[6-[[2-[4-(3,3-difluorocyclobutoxy)-6-methyl-2-pyridyl]acetyl]amino]pyridazin-3-yl]-2-fluoro-butyl]-N-methyl-triazole-4-carboxamide;2-Pyridineacetamide, 4-[(3,3-difluorocyclobutyl)oxy]-N-[6-[(3R)-3-fluoro-4-[4-[(methylamino)carbonyl]-1H-1,2,3-triazol-1-yl]butyl]-3-pyridazinyl]-6-methyl-;IACS-6274 | | CAS: | 1853164-83-6 | | MF: | C24H27F3N8O3 | | MW: | 532.52 | | EINECS: | | | Product Categories: | APIs | | Mol File: | 1853164-83-6.mol |  |
| | IPN-60090 Chemical Properties |
| density | 1.47±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 31.43 mg/mL (59.02 mM; Need ultrasonic) | | pka | 11.74±0.70(Predicted) | | form | Solid | | color | Pink to red |
| | IPN-60090 Usage And Synthesis |
| Uses | IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers[1][2]. | | in vivo | IPN60090 (3 mg/kg for i.v.; 10 mg/kg for p.o.) has excellent pharmacokinetic properties, with CL=4.1 mL/min/kg, t1/2=1 hour, Cmax=19 μM, F%=89%[2].
IPN-60090 (oral administration; 100 mg/kg; twice daily; 30 days) shows similar efficacy and target engagement to CB-839 (HY-12248) dosed orally at 250 mg/kg twice daily. And the 100 mg/kg BID dose of IPN-60090 is a tolerated dose for the following model study[2].IPN-60090 (oral administration; 100 mg/kg; twice daily; 30 days; monotherapy or in combination with TAK228 (HY-13328)) causes tumor growth inhibition. IPN-60090 alone demonstrates robust in vivo target engagement in a dose-dependent manner. The glutamate/glutamine ratios and the free plasma concentrations of IPN-60090 at 4 hours post-dose on both day 4 and day 28 are all decreased[2]. Furthermore, IPN-60090 in combination with TAK228 strongly causes an 85% tumor growth inhibition, IPN-60090 alone causes a 28% tumor growth inhibition in vivo[2]. | Animal Model: | Female CD-1 mice[2] | | Dosage: | 3 mg/kg for i.v.; 10 mg/kg for p.o. (Pharmacokinetic Analysis) | | Administration: | Intravenous injection and oral administration | | Result: | CL (4.1 mL/min/kg), t1/2 (1 hour) for i.v.; Cmax (19 μM), F% (89%) for p.o.. |
| Animal Model: | Ru337 non-small cell lung cancer patient-derived xenograft (PDX) subcutaneous mouse model as monotherapy or in combination[2] | | Dosage: | 100 mg/kg | | Administration: | Oral administration; 100 mg/kg; twice daily; 30 days; monotherapy or in combination with TAK228 | | Result: | Exhibited an improvement in the combination regimen group over either single agent. |
| | References | [1] Maria Emilia Di Francesco, et al. Gls1 inhibitors for treating disease. WO2016004404A2.
[2] Michael J Soth, et al. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem. 2020 Nov 12;63(21):12957-12977. DOI:10.1021/acs.jmedchem.0c01398 |
| | IPN-60090 Preparation Products And Raw materials |
|